Biotest AG - Company Profile
Powered by 
All the sales intelligence you need on Biotest AG in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Biotest AG fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Biotest AG.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Biotest AG (Biotest), a subsidiary of Grifols SA, provides pharmaceutical and biotherapeutic drugs. It develops, manufactures, and distributes biological medicines through its value chain from preclinical and clinical development to sales. Its main products include clotting factors, immunoglobulins, albumin, and monoclonal antibodies in clinical development. The company specializes in the areas of clinical immunology, haematology, and intensive care medicine. Biotest distributes its products through local marketing partners and distributors in Europe, North America, South America, Asia, the Middle East, and Africa. It has subsidiaries and sales companies in Austria, Switzerland, France, Great Britain, Italy, Hungary and Spain, and Brazil. Biotest is headquartered in Dreieich, Hessen, Germany.
Headquarters
Germany
Address
Landsteinerstr. 5, Dreieich, Hessen, 63303
Website
www.biotest.com
Telephone
49 610 38010
No of Employees
2,698
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BIO0 (HAM)
Revenue (2024)
$732.1M
-10.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-368.8%
(2024 vs 2023)
Market Cap*
$743.2M
Net Profit Margin (2024)
XYZ
-401.1%
(2024 vs 2023)
* As of and is in US$
Biotest AG premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Clinical Immunology Therapeutic Area: | Cytotect CP Biotest |
| Cytotect CP Biotest: For immunosuppressive therapy. | Fovepta |
| Fovepta: For hepatitis B in neonates. | Hepatect CP |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In December, the company received approval from the U.S. Food and Drug Administration (FDA) for Fesilty (fibrinogen, human-chmt) to Treat Congenital Fibrinogen Deficiency. |
| 2025 | New Products/Services | In October, the company introduced Yimmugo, a new intravenous polyvalent human normal immunoglobulin (IVIg) to treat primary immunodeficiencies, in the US. |
| 2025 | Contracts/Agreements | In March, the company signed a delisting agreement with its major shareholder, Grifols, S.A., which holds about 97.14% of the company’s ordinary shares and 46.22% of its preferred shares. Based on this agreement, the Management Board plans to apply for the withdrawal of the company’s ordinary and preferred shares from trading on the regulated market (Prime Standard) of the Frankfurt Stock Exchange. |
Competitor Comparison
| Key Parameters | Biotest AG | Takeda Pharmaceutical Co Ltd | BioNTech SE | Stratec SE | Formycon AG |
|---|---|---|---|---|---|
| Headquarters | Germany | Japan | Germany | Germany | Germany |
| City | Dreieich | Chuo-Ku | Mainz | Birkenfeld | Martinsried |
| State/Province | Hessen | Tokyo | Rheinland-Pfalz | Rheinland-Pfalz | Bayern |
| No. of Employees | 2,698 | 47,029 | 7,807 | 1,395 | 250 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jorg Schuttrumpf | Chief Executive Officer | Senior Management | 2025 | - |
| Bernhard Ehmer, MD | Chairman | Non Executive Board | 2022 | 71 |
| Monika Baumann | Head - Investor Relations | Senior Management | - | - |
| Dirk Schuck | Director | Non Executive Board | 2022 | 48 |
| David Bell | Director | Non Executive Board | 2022 | 72 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer